Insider Buying: Dova Pharmaceuticals Inc (NASDAQ:DOVA) Major Shareholder Purchases $298,049.91 in Stock

Share on StockTwits

Dova Pharmaceuticals Inc (NASDAQ:DOVA) major shareholder Life Sciences Maste Perceptive bought 20,541 shares of the firm’s stock in a transaction dated Wednesday, July 3rd. The stock was purchased at an average price of $14.51 per share, with a total value of $298,049.91. The purchase was disclosed in a legal filing with the SEC, which is available at this hyperlink. Large shareholders that own 10% or more of a company’s shares are required to disclose their transactions with the SEC.

Life Sciences Maste Perceptive also recently made the following trade(s):

  • On Friday, June 28th, Life Sciences Maste Perceptive bought 427,209 shares of Dova Pharmaceuticals stock. The stock was purchased at an average price of $13.35 per share, with a total value of $5,703,240.15.

Shares of NASDAQ DOVA opened at $16.11 on Monday. The company has a market cap of $454.83 million, a P/E ratio of -6.20 and a beta of 2.56. Dova Pharmaceuticals Inc has a 12-month low of $5.62 and a 12-month high of $29.72. The company has a current ratio of 4.46, a quick ratio of 4.27 and a debt-to-equity ratio of 0.20. The business has a 50 day moving average of $10.47.

Dova Pharmaceuticals (NASDAQ:DOVA) last announced its quarterly earnings results on Tuesday, May 7th. The company reported ($0.58) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.68) by $0.10. The business had revenue of $4.00 million for the quarter, compared to the consensus estimate of $3.46 million. Dova Pharmaceuticals had a negative return on equity of 87.20% and a negative net margin of 521.67%. Equities research analysts forecast that Dova Pharmaceuticals Inc will post -2.1 earnings per share for the current year.

DOVA has been the subject of several research reports. BidaskClub lowered Dova Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday, April 10th. Wedbush started coverage on Dova Pharmaceuticals in a report on Wednesday, May 22nd. They issued an “outperform” rating and a $19.00 price target on the stock. HC Wainwright reissued a “buy” rating and issued a $18.00 price target on shares of Dova Pharmaceuticals in a report on Friday, April 26th. Finally, Evercore ISI raised Dova Pharmaceuticals from an “in-line” rating to an “outperform” rating and set a $15.00 price target on the stock in a report on Monday, July 1st. One analyst has rated the stock with a sell rating, three have assigned a hold rating and seven have assigned a buy rating to the company. Dova Pharmaceuticals presently has a consensus rating of “Buy” and a consensus target price of $29.11.

Several hedge funds and other institutional investors have recently made changes to their positions in DOVA. PNC Financial Services Group Inc. raised its stake in Dova Pharmaceuticals by 14,705.9% during the 4th quarter. PNC Financial Services Group Inc. now owns 5,034 shares of the company’s stock valued at $38,000 after acquiring an additional 5,000 shares in the last quarter. Rhumbline Advisers raised its stake in Dova Pharmaceuticals by 46.1% during the 4th quarter. Rhumbline Advisers now owns 15,343 shares of the company’s stock valued at $116,000 after acquiring an additional 4,843 shares in the last quarter. Two Sigma Investments LP bought a new stake in Dova Pharmaceuticals during the 4th quarter valued at $136,000. Squarepoint Ops LLC bought a new stake in Dova Pharmaceuticals during the 4th quarter valued at $137,000. Finally, DekaBank Deutsche Girozentrale raised its stake in Dova Pharmaceuticals by 22.0% during the 1st quarter. DekaBank Deutsche Girozentrale now owns 13,300 shares of the company’s stock valued at $336,000 after acquiring an additional 2,400 shares in the last quarter. 30.18% of the stock is currently owned by institutional investors and hedge funds.

Dova Pharmaceuticals Company Profile

Dova Pharmaceuticals, Inc, a pharmaceutical company, focuses on acquiring, developing, and commercializing drug candidates for thrombocytopenia disease. The company's lead product candidate is DOPTELET that is indicated for the treatment of thrombocytopenia in adult patients with chronic liver disease scheduled to undergo a procedure.

Recommended Story: How Does the Quiet Period Work?

Insider Buying and Selling by Quarter for Dova Pharmaceuticals (NASDAQ:DOVA)

Receive News & Ratings for Dova Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dova Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

JPMorgan Chase & Co. Increases AvalonBay Communities  Price Target to $224.00
JPMorgan Chase & Co. Increases AvalonBay Communities Price Target to $224.00
Brightsphere Investment Group  Lifted to “Hold” at Zacks Investment Research
Brightsphere Investment Group Lifted to “Hold” at Zacks Investment Research
PLDT  Rating Lowered to Hold at Zacks Investment Research
PLDT Rating Lowered to Hold at Zacks Investment Research
AtriCure  Stock Rating Lowered by Northland Securities
AtriCure Stock Rating Lowered by Northland Securities
Bradesco Corretora Reiterates “Neutral” Rating for Ternium
Bradesco Corretora Reiterates “Neutral” Rating for Ternium
Meridian Bioscience  Rating Lowered to Sell at ValuEngine
Meridian Bioscience Rating Lowered to Sell at ValuEngine


 
© 2006-2019 Zolmax.